In addition to its in vitro effects, CS also reduced serum or tissue levels of cytokines with inhibition of the NFκB pathway in animal models of inflammatory diseases such as spinal cord injury [16], atopic dermatitis [19] and rheumatoid arthritis [88]. Here, NFKB1 is linked to atopic eczema.